Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population

• Published in: Annals of clinical and translational neurology 2021-02, Vol.8 (2), p.385-394
• Main Authors: Fernandez‐Diaz, Eva, Perez‐Vicente, Jose A., Villaverde‐Gonzalez, Ramon, Berenguer‐Ruiz, Leticia, Candeliere Merlicco, Antonio, Martinez‐Navarro, Maria Luisa, Gracia Gil, Julia, Romero‐Sanchez, Carlos M., Alfaro‐Saez, Arantxa, Diaz, Inmaculada, Gimenez‐Martinez, Juana, Mendez‐Miralles, Maria Angeles, Millan‐Pascual, Jorge, Jimenez‐Pancho, Javier, Mola, Santiago, Sempere, Angel P.
• Format: Article
• Language: English
• Subjects: Adult; Antibodies, Monoclonal, Humanized - therapeutic use; Brain - diagnostic imaging; Clinical trials; Disease Progression; Female; Histamine; Humans; Immunologic Factors - therapeutic use; Infections; Injection Site Reaction; Magnetic Resonance Imaging; Male; Middle Aged; Monoclonal antibodies; Multiple sclerosis; Multiple Sclerosis, Chronic Progressive - diagnostic imaging; Multiple Sclerosis, Chronic Progressive - drug therapy; Multiple Sclerosis, Chronic Progressive - physiopathology; Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - physiopathology; Patients; Retrospective Studies; Spain; Spinal Cord - diagnostic imaging; Treatment Outcome
• ISSN: 2328-9503; 2328-9503
• DOI: 10.1002/acn3.51282

Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for multiple sclerosis (MS) in a real‐world clinical setting. Methods We conducted a retrospective study including consecutive patients from nine public hospitals in south‐eastern Spain who received ocrelizumab after it was approved. Results A total of 228 MS patients were included (144 with relapsing–remitting MS [RRMS], 25 secondary progressive MS [SPMS], and 59 primary progressive MS [PPMS]). Median follow‐up period was 12 months (range, 1‐32). No evidence of disease activity (NEDA) status at year 1 was achieved in 91.2% of the relapsing MS (RMS) population, while disability progression was detected in 37.5% of the PPMS patients (median follow‐up period, 19 months). The most common adverse events reported were infusion‐related reactions and infections, with the most common infections being urinary tract infections followed by upper respiratory infections and COVID‐19. Interpretation The preliminary results in our real‐world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile.